The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. https://caoimherlya489700.blogsidea.com/45735642/glp-3-retatrutide-a-comparative-analysis